Evidence map›Paper›PMID 32568200›Full record

ReviewJournal of Alzheimer's disease : JAD2021

Polyphenols as Potential Metal Chelation Compounds Against Alzheimer's Disease.

Johant Lakey-Beitia, Andrea M Burillo, Giovanni La Penna, Muralidhar L Hegde, K S Rao

Open access · greenAbstract readReview
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 160 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. The interactions of copper, glutamate, and cuproptosis: insights into brain health and Alzheimer's disease pathology.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  7. Review
  8. Review
  9. Frontiers in nutrition · 2026
    Article
  10. Article
  11. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  12. Akkermansia muciniphila MucNature communications · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Johant Lakey-BeitiaCentre for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Clayton, City of Knowledge, Panama.
Andrea M BurilloCentre for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Clayton, City of Knowledge, Panama.
Giovanni La PennaNational Research Council, Institute of Chemistry of Organometallic Compounds, Sesto Fiorentino (FI), Italy.
Muralidhar L HegdeDepartment of Radiation Oncology, Houston Methodist Research Institute, Houston, TX, USA.
K S RaoCentre for Neuroscience, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Clayton, City of Knowledge, Panama.
Instituto de Investigaciones Científicas y Servicios de Alta Tecnología · PAHouston Methodist · USNational Research Council · IT

Funding

Defining the altered FUS-PARP-1-DNA Ligase III axis and its implications to nuclear and mitochondrial genome damage response in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)RF1NS112719 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HEGDE, MURALIDHAR L · 2020 to 2020
$2.0M
Etiological Linkage of DNA Damage/Repair Deficiency in Neurodegenerative DiseasesR01NS088645 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HEGDE, MURALIDHAR L · 2015 to 2019
$1.8M
NINDS NIH HHS R01 NS088645NINDS NIH HHS RF1 NS112719
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disease affecting more than 50 million people worldwide. The pathology of this multifactorial disease is primarily characterized by the formation of amyloid-β (Aβ) aggregates; however, other etiological factors including metal dyshomeostasis, specifically copper (Cu), zinc (Zn), and iron (Fe), play critical role in disease progression. Because these transition metal ions are important for cellular function, their imbalance can cause oxidative stress that leads to cellular death and eventual cognitive decay. Importantly, these transition metal ions can interact with the amyloid-β protein precursor (AβPP) and Aβ42 peptide, affecting Aβ aggregation and increasing its neurotoxicity. Considering how metal dyshomeostasis may substantially contribute to AD, this review discusses polyphenols and the underlying chemical principles that may enable them to act as natural chelators. Furthermore, polyphenols have various therapeutic effects, including antioxidant activity, metal chelation, mitochondrial function, and anti-amyloidogenic activity. These combined therapeutic effects of polyphenols make them strong candidates for a moderate chelation-based therapy for AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntioxidantsChelating AgentsCopperHumansOxidative StressPolyphenolsZincAmyloid beta-PeptidesAntioxidantsChelating AgentsCopperPolyphenolsZincAlzheimer’s diseaseamyloid-βcopperironmetal chelation therapymetalloproteinspolyphenolszinc

Identifiers

PMID32568200
PMCPMC7809605
OpenAlexW3036123142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.